Virtual Library

Start Your Search

Virginie Westeel



Author of

  • +

    FP09 - Screening and Early Detection (ID 175)

    • Event: WCLC 2020
    • Type: Posters (Featured)
    • Track: Screening and Early Detection
    • Presentations: 1
    • Moderators:
    • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
    • +

      FP09.05 - Driver Oncogenic Alterations and Indoor Radon in NSCLC Patients From the IFCT Biomarker Cohort: Bioradon France Study (ID 1176)

      00:00 - 00:00  |  Author(s): Virginie Westeel

      • Abstract
      • Slides

      Introduction

      Radon is a radioactive gas, considered as the leading cause of lung cancer in non-smokers. In a previous work, we studied the correlation between the estimation of radon concentration from the French Indoor Radon Map (Institut de Radioprotection et de Sûreté Nucléaire, IRSN) and the regional prevalence of driver alterations in a cohort of 116.424 NSCLC patients in France (Mezquita et al, WCLC 2018). The prevalence of driver oncogene alterations was significantly higher in high-radon areas but clinical data were not available. We aim to confirm this hypothesis in an annotated database of NSCLC patients with matched molecular data available for adjustment (Barlesi et al, Lancet 2016).

      Methods

      Retrospective assessment of patients with NSCLC tested for EGFR/BRAF/HER2/KRAS mutations (m) and ALK fusion from the 28 Platform led by the National Cancer Institute between Apr.2012 and Apr.2013, and included in the Biomarkers France dataset. We studied the association between the prevalence of driver oncogenic alterations (EGFR/ALK/BRAF/HER2/KRAS) and the radon mean concentration in the area where the patient was born according to the IRSN Map. Adjustment on age, gender and smoking was performed.

      Results

      Out of 17664 patients, we analyzed 3994 with birthplace available: 63% males, 82% smokers, with a median age of 64 years [18-94]. Lung cancer tumors were mostly adenocarcinoma (76%), followed by other histologies (18%) and squamous (6%). By molecular alterations: 468 tumors harbor EGFRm (12%), 129 ALK (3%), 89 BRAFm (2%), 32 HER2m (1%), 985 KRASm (25%); 2273 wildtype or harbor other non-driver alterations (control; 57%). Adenocarcinoma histology (83.7% vs. 80.2%, p=0.0034), and non-smoker habit (19.5% vs. 16.5%, p=0.0251) were more common in radon high-risk group (comparatively at the low risk group). The mean radon concentration by birthplace was 74.36 Bq/m3 ±53.28SD [range 16.6-622.3], and by molecular groups: EGFRm 72.49 Bq/m3 ± 47.98 SD [16.6-461.4], ALK 80.24 Bq/m3 ±55.22SD [19.3-384.7], BRAFm 73.22 Bq/m3 ±47.86SD [19.3-319.3], HER2m 72.74 Bq/m3 ±39.51SD Bq/m3 [27.8-231.3], KRASm 71.79 Bq/m3 ±53.32SD [16.6-576.8] and control group 75.67 Bq/m3 ± 54.5SD [16.6-622.3] (p=0.20). The prevalence of driver alterations was higher in high-radon areas (table 1; p=0.0472); but no significant difference was observed after adjustment on age, gender and smoking.

      Low radon
      <50 Bq/m3

      High radon
      50 Bq/m3

      P value

      P value adjusted*

      EGFR

      Mutation

      N (%)

      155 (11.4%)

      313 (13.2%)

      0.1218

      0.3024

      Control (1)

      N (%)

      1199 (88.6)

      2059 (86.8)

      ALK

      Fusion

      N (%)

      42 (3.4%)

      87 (4.1%)

      0.3272

      0.4708

      Control (1)

      N (%)

      1199 (96.6)

      2059 (95.9)

      BRAF

      Mutation

      N (%)

      32 (2.6%)

      57 (2.7%)

      0.8708

      0.9865

      Control (1)

      N (%)

      1199 (97.4)

      2059 (97.3)

      HER2

      Mutation

      N (%)

      7 (0.6%)

      25 (1.2%)

      0.0880

      0.1781

      Control (1)

      N (%)

      1199 (99.4)

      2059 (98.8)

      KRAS

      Mutation

      N (%)

      375 (31.3%)

      610 (29.6%)

      0.3227

      0.3478

      Control (2)

      N (%)

      824 (68.7)

      1449 (70.4)

      DRIVER

      Positive

      N (%)

      236 (16.4%)

      482 (19%)

      0.0472

      0.2128

      Control (1)

      N (%)

      1199 (83.6)

      2059 (81)

      (1) population no EGFRm, noBRAFm, no HER2m and no ALKr
      (2) population no EGFRm, noBRAFm, no HER2m, no ALKr and no KRASm

      *adjustment on age, gender and smoking

      Conclusion

      We observed a higher prevalence of driver oncogenic alterations in NSCLC patients born in high radon areas; but no significant difference was observed after adjustment on age, gender and smoker. This study warrants further research on radon gas and driver oncogenes.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    IS10 - Industry Symposium Sponsored by Bristol Myers Squibb: Thoracic Cancers, New Developments with IO (ID 287)

    • Event: WCLC 2020
    • Type: Industry Symposium
    • Track:
    • Presentations: 4
    • +

      IS10.01 - Welcome and Introductions (ID 4349)

      13:00 - 14:00  |  Presenting Author(s): Virginie Westeel

      • Abstract

      Abstract not provided

    • +

      IS10.02 - What Is the Role of IO in Non-Metastatic NSCLC? (ID 4350)

      13:00 - 14:00  |  Presenting Author(s): Virginie Westeel

      • Abstract

      Abstract not provided

    • +

      IS10.04 - Non-Metastatic and Metastatic NSCLC Q&A (ID 4352)

      13:00 - 14:00  |  Presenting Author(s): Virginie Westeel

      • Abstract

      Abstract not provided

    • +

      IS10.06 - Mesothelioma Q&A and Closing Remarks (ID 4354)

      13:00 - 14:00  |  Presenting Author(s): Virginie Westeel

      • Abstract

      Abstract not provided